CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Clinomics Inc (Parent) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Clinomics Inc (Parent)
301-3, 110 Dong, 50
UNIST-gil, Eonyang-eup, Ulju-gun
ULSAN, 44919  South Korea Fax: +82 3180667274f:+82 3180667274
Business Summary
Clinomics Inc is a Korea-based company engaged in the development of genome diagnostic tests and liquid biopsies. The Company's main businesses are multi-omics-based service business and liquid biopsy-based cancer diagnosis and screening business. The multi-omics-based service business provides products and services that predict physical characteristics and diseases based on genome diagnosis and tests, and provides early diagnosis services for major diseases such as cancer based on multi-omics. The liquid biopsy-based cancer diagnosis and screening business sells medical devices that diagnose patients by extracting blood cells and deoxyribonucleic acid (DNA), and diagnostic and monitoring kits for cancer mutations in patients. It is also develops products that diagnoses cancer early with blood.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202012/31/2019Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8071 Medical laboratories
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Chief Executive Officer, Director Jong TaeJung 59
Co-Chief Executive Officer, Director Byeong CheolKim 3/28/2023
Director Jong HwaPark 55 3/28/2023 3/28/2022

General Information
Outstanding Shares: 31,664,602 (As of 8/10/2023)
Fax Number: +82 3180667274


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, September 6, 2023